The same authors performed a further analysis of factors predicting a good response to exenatide treatment and showed that patients whose disease duration was less than four years showed a trend towards a lower disease burden.
← all excerpts
The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.
1
—
—